217 related articles for article (PubMed ID: 28860121)
1. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
2. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
4. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
5. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
6. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
[TBL] [Abstract][Full Text] [Related]
7. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
[TBL] [Abstract][Full Text] [Related]
8. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Chowdhry S; Zanca C; Rajkumar U; Koga T; Diao Y; Raviram R; Liu F; Turner K; Yang H; Brunk E; Bi J; Furnari F; Bafna V; Ren B; Mischel PS
Nature; 2019 May; 569(7757):570-575. PubMed ID: 31019297
[TBL] [Abstract][Full Text] [Related]
9. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
11. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
13. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
[TBL] [Abstract][Full Text] [Related]
14. NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Li XQ; Lei J; Mao LH; Wang QL; Xu F; Ran T; Zhou ZH; He S
Front Oncol; 2019; 9():736. PubMed ID: 31448236
[TBL] [Abstract][Full Text] [Related]
15. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
16. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy.
Kim M; Kim H; Kang BG; Lee J; Kim T; Lee H; Jung J; Oh MJ; Seo S; Ryu MJ; Sung Y; Lee Y; Yeom J; Han G; Cha SS; Jung H; Kim HS
Theranostics; 2023; 13(14):5075-5098. PubMed ID: 37771778
[No Abstract] [Full Text] [Related]
18. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
20. Distinct IDH1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
